Merck highlights progress on HIV, hypertension, cervical cancer drugs
RAHWAY, N.J. – Merck got off to an excellent start in the first quarter of 2024. Compared to the first quarter of 2023, results were up where you want to see them go up, like sales, and down where you want to see them go down, like expenses. Buoyed by the …